Iodixanol in cardioangiography in patients with coronary artery disease. Tolerability, cardiac and renal effects.
Iodixanol is a new nonionic, dimeric contrast medium. With the addition of 18 mmol/l Na+ and 0.3 mmol/l Ca++ to iodixanol 320 mg I/ml a plasma-isotonic solution was obtained. The purpose was to evaluate the suitability of iodixanol for use in cardioangiography by determining the diagnostic efficacy, patient tolerability, and cardiac and renal side-effects. Initially, 14 patients with coronary artery disease were examined using iodixanol. A double-blind, randomized study was then performed in 72 patients, comparing iodixanol and iohexol. Serum and urine were sampled before the examination, and one and 2 days after. The diagnostic information was good and the number of adverse events low with iodixanol. The patients reported significantly less of a sensation of warmth following injection of iodixanol than iohexol. Our results also indicate that iodixanol 320 mg I/ml influences renal function to a lesser degree than does iohexol 350 mg I/ml. We therefore conclude that isotonic iodixanol is a safe contrast medium for use in cardioangiography.
Kløw
N E
NE
Department of Radiology, National Hospital, Oslo, Norway.
Levorstad
K
K
Berg
K J
KJ
Brodahl
U
U
Endresen
K
K
Kristoffersen
D T
DT
Laake
B
B
Simonsen
S
S
Tofte
A J
AJ
Lundby
B
B
D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000009:adverse effects; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging*; D004311:Double-Blind Method; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007472:Iohexol / Q000009:adverse effects; D007668:Kidney / Q000187:drug effects; D008875:Middle Aged; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D014283:Triiodobenzoic Acids; D007472:Iohexol; C044834:iodixanol